Renovo Share Discussion Threads

[daytraders] 01/8/2011 16:49

at the very worst 17p/18p in cash alone imo, but still think over 20p when all done and dusted.

[daytraders] 01/8/2011 15:12

they just want your shares, there dropping price on back of bad markets and hopeing some may sale.

[smith99] 30/7/2011 23:12

there really isnt a downside to this share, reminds me a bit like Ceres Power which I also grabbed some before at a riddiculous 29p, got most of that in cash and a cracking product once it gets teething problems sorted. Just no down side providing you are prepared to wait a little.

[smith99] 29/7/2011 00:37

just had a text from Terry saying that he still maintains 7p by the end of the week. He also wanted to know how many squirrels were in my garden as an average as his wanted to buy a lottery ticket for Fridays Draw, something aint right with that lad!

lol only kidding terry, I wouldnt really give you my number.

If you happen to search his posts, youll see he has a habit of being a plonker on other forums too

[mister md] 26/7/2011 16:10

Renovo Group shares bought by Kestrel
Mon 2:57 pm by Jon Mainwaring

Despite the disappointment of Juvista, Renovo still has 18.5 pence per share of cash and intellectual property relating to other anti-scarring technologies

Renovo Group (LON:RNVO) announced today that Kestrel Opportunities acquired 380,000 shares in the biotech business at 14.5 pence per share last Friday.

Kestrel Opportunities now holds more than 8.9 million shares in the business, representing approximately 4.7 per cent of the company's share capital

Kestrel Opportunities is an investment vehicle in which Renovo non-executive director Max Royde holds a shareholding in. It is also advised by Kestrel Partners, which Royde is a partner of and has a beneficial interest in.

Last Wednesday, Renovo announced it had reduced its development activities and expenditure, made all of its staff redundant and significantly reduced the size of its board. This was the result of strategic review that followed February's revelation that the company's lead drug, the scar treatment Juvista, failed to meet its goals in a major clinical trial.

The company also reported that its cash position at the end of June was £35 million (approximately 18.5 pence per share).

As well as its cash pile, the firm also has intellectual property relating to two early stage products: Prevascar and Adaprev. Prevascar is a treatment targeted at improving the appearance of scarring in skin, while Adaprev is a Class III medical device in the EU for the reduction of tendon adhesions.

The firm is considering delisting from the London Stock Exchange's main market and moving down to the Alternative Investment Market.

[hollerich1] 26/7/2011 11:59

has anyone seen that idiot terry.

[wh1spa] 26/7/2011 09:33

Look at the performance of GHT since Royde has been on the scene. He obviously has something lined up. His Kestrel Opps fund which is a large holder in both GHT and RNVO is considered as a low risk fund focusing on small undervalued companies.

[holly_dog] 26/7/2011 08:56

This looks good, hopefully a leak with some IP sales

[mister md] 26/7/2011 08:49

even more so now ... wonder what they are planning ?

[daytraders] 25/7/2011 13:09

RENOVO GROUP PLC

("Renovo" or the "Company")

(LSE: RNVO)

Notification of Interest and Director's Dealings


Renovo Group plc has received notification that on 22 July 2011, Kestrel Opportunities, a cell of Guernsey Portfolios PCC Limited ("Kestrel Opportunities"), acquired 380,000 ordinary shares in the Company at a price of 14.5 pence per share.

Kestrel Partners LLP, which Max Royde (Non-executive Director of the Company) is a partner of and holds a beneficial interest in, is the investment manager to Kestrel Opportunities. Mr Royde is also a shareholder in Kestrel Opportunities.

Kestrel Opportunities holds 8,916,942 ordinary shares in the Company, which represents approximately 4.7 per cent of the Company's issued share capital.


For further information please contact:

Buchanan Communications:

Tim Anderson, Lisa Baderoon, Catherine Breen +44(0) 20 7466 5000

[holly_dog] 20/7/2011 14:23

Adaprev is classified as a medical device which is handy, as it means streamlined approval so if this trial works then there is some real value in the IP.

I think we will get a positive announcement on sale of other IP in the coming months to boost the cash further

Rich - they will do whatever will maximise shareholder value.

[daytraders] 20/7/2011 13:28

imo 18p/19p cash even if all trials fail, if trials succesfull the skys the limit, a real no brainer here.

[hollerich1] 20/7/2011 13:12

guys lets look at this case secnario, supposing the remaining trials are all very sucessfull, could the company retract there sale statement and try and liecence the sucess rather than outright sale, as they done with shire on juvista, this is just a thought. any other opinion is highly regarded.

[holly_dog] 20/7/2011 12:44

Yeh know what you mean GS...price isn't right for me though, my holding is pretty heavy and average is 15p, so unless it comes back down to about 14.25 on the buy I'm just going to wait it out.

I can't believe there aren't any more that picked up on this, maybe a some broker notes+overnight press commentary might perk some interest